Erschienen in:
21.01.2022 | Short Communication
Empagliflozin does not affect left ventricular diastolic function in patients with type 2 diabetes mellitus and coronary artery disease: insight from the EMPA-HEART CardioLink-6 randomized clinical trial
verfasst von:
Archana Rai, Kim A. Connelly, Subodh Verma, C. David Mazer, Hwee Teoh, Ming-Yen Ng, Idan Roifman, Adrian Quan, Marina Pourafkari, Laura Jimenez-Juan, Venkat Ramanan, Yin Ge, Djeven P. Deva, Andrew T. Yan
Erschienen in:
Acta Diabetologica
|
Ausgabe 4/2022
Einloggen, um Zugang zu erhalten
Excerpt
Sodium-glucose co-transporter 2 inhibitors (SGLT2i) have demonstrated promising results in reducing cardiovascular mortality and hospitalization due to heart failure (HF) in patients with type 2 diabetes mellitus (T2DM) and heart failure and reduced ejection fraction (HFrEF) [
1]. LV diastolic dysfunction is prevalent in patients with T2DM (~ 40%), however the impact of SGLT2i on LV diastolic function has not been well studied. Therefore, we sought to investigate the effect of the SGLT2i empagliflozin on LV diastolic function in patients with T2DM and coronary artery disease (CAD) using cardiac magnetic resonance imaging (CMR). …